New PET scan could spot hidden aggressive prostate cancer in men avoiding treatment
NCT ID NCT07285057
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding a special PET scan (using a radioactive tracer called flotufolastat F18) to the standard MRI can better find aggressive prostate cancer in men who are currently on active surveillance. About 120 men with low- or favorable intermediate-risk prostate cancer will get both scans before a confirmatory biopsy. The goal is to see if the PET scan catches cancers that MRI misses, helping doctors decide who truly needs treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flotufolastat F18 (POSLUMA®), a radioactive tracer used in PET/CT imaging
What this could lead to
If successful, this could lead to a more accurate imaging method to detect aggressive prostate cancer early, helping men on active surveillance avoid unnecessary biopsies or delayed treatment.
What could go wrong
This is a small, early-phase study (120 participants) at a single center. The imaging agent is already FDA-approved, but its added benefit over standard MRI is unproven, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Hospital / Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••